• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

French development agency AFD commits €1.5m to DNDi for the development of two news drugs for malaria

Paris, France / Geneva, Switzerland — 14 Jun 2006
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

AFD (Agence Française de Développement) and DNDi (Drugs for Neglected Diseases initiative) finalised a partnership agreement today to support the development of two new drugs for malaria.
[Français]

The objective of the FACT (Fixed-dose Artesunate Combination Therapies) programme, initiated in 2002 by DNDi and its partners, is to provide two new Artesunate-based Combination Therapies (ACTs) for millions of malaria patients in Africa, Asia, and Latin America. These combinations, recommended by the World Health Organisation, will not only save lives but also deter the rapid development of parasite resistance to these drugs, as happened to chloroquine. The two new treatments « Artesunate/Amodiaquine » and « Artesunate/Mefloquine » will combine two proven antimalarials in a single tablet, and will offer two advantages over existing treatments:

  • Simpler dosage regimen with less tablets to take and, thereby, improved treatment compliance;
  • Reduced cost of treatment.

« This partnership with DNDi stems from the commitment of AFD to support innovative initiatives with public and private partnerships, aimed not only at providing health solutions to populations in developing countries in need of appropriate treatments, but also at reinforcing the technological capacity and know-how of developing countries », said Jean Michel Severino, Executive Director of AFD.

Under the provisions of this agreement, the financial contribution of AFD will be provided exclusively in the final stage of the development of these two new treatments, which will include:

  • The registration of the products in one endemic country each in Africa, Asia and South America;
  • Technology transfer to industrial partners in the endemic regions for the production of the drugs;
  • Assistance to those in charge of national programmes in the countries concerned to help them include these new treatments in the existing therapeutic protocols.

The agreement amounts to €1.5m payable over 2006 and 2007
« The support provided by AFD will play a determining role at this stage of our project. For many years, the DNDi malaria programme has brought together academics and private partners like Sanofi Aventis, and it has received for its clinical development stage the support of Médecins Sans Frontières and the European Union. This contribution of AFD, the first one from France since the launch of DNDi, is an encouraging sign that certain governments are starting to perceive the urgency to invest in R&D on neglected diseases, to promote the development of new, more effective and adapted treatments, », said Dr Bernard Pecoul, Executive Director of DNDi.

DNDi (Drugs for Neglected Diseases initiative) is a non-profit organisation, created in 2003 to develop new drugs against neglected diseases, which affect massively the poorest populations in developing countries. The research and development portfolio of DNDi currently includes 20 projects on human African trypanosomiasis (also known as « sleeping sickness »), Chagas disease, leishmaniasis, and malaria. The other DNDi founding members are 5 research institutions: Institut Pasteur, Kenya Medical Research Institute (KEMRI), Indian Council of Medical Research (ICMR), the Foundation Oswaldo Cruz in Brazil, the Ministry of Health in Malaysia, and the humanitarian organisation Médecins sans Frontières. The special Programme for Research and Training in Tropical Diseases (TDR) from WHO/UNICEF/World Bank acts as a permanenent observer to the initiative. Another DNDi mission is to support the development of research capacities in endemic countries, and increase public awareness on the necessity to increase our efforts in R&D on neglected diseases: www.dndi.org

For further information, please contact

Jean-François Alesandrini at jfalesandrini@dndi.org;
+41 22 906 92 43 or
mobile +41 (0)79 596 5066

or Ann-Marie SEVCSIK at amsevcsik@dndi.org;
+1-646-258-8131 or
+41 (0)79 814 9147)

Funding Malaria

Read, watch, share

Loading...
Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Hand holding pill
Publications
23 May 2022

Best science for all

Laboratory activities
Press releases
18 May 2022

Consortium formed to discover antivirals for COVID-19 receives NIH funding to develop globally accessible treatments for pandemics

Researcher working in a laboratory setting
News
18 May 2022

Health Journalists from Africa receive grants to report on COVID-19

After a serious outbreak of dengue fever in the Chinatown area of Bangkok in which a man died, the Bangkok Metropolitan Administration came in to fumigate the area and advise locals on possible breeding ground of mosquitos.
Press releases
29 Apr 2022

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

News
22 Apr 2022

DNDi calls for nominations for a new Audit Committee Member

Microscope and computer
Press releases
20 Apr 2022

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Woman looking up
Stories
13 Apr 2022

Early diagnosis and treatment can save millions of lives

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License